Parkinson’s Disease

Serina Therapeutics, Huntsville, Ala., July 23, 2026 Serina Therapeutics announced the successful completion of enrollment and dosing in Cohort...

Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...

SAN DIEGO, July 15, 2026 Sinopia Biosciences announced the publication of preclinical research in Science Translational Medicine supporting SB-0110,...

VANCOUVER, British Columbia, July 6, 2026 Grey Matters Health Inc. announced the delivery of its first FDA-cleared CareMiBrain™ brain-dedicated...

NEW YORK, July 7, 2026 The American Parkinson Disease Association (APDA) has announced the launch of “Bridging Mental Health...

SAN DIEGO, July 7, 2026 Kenai Therapeutics has announced the successful completion of patient enrollment in the Phase 1b/2a...

BOSTON, July 6, 2026 CervoMed Inc. announced that new clinical findings on its investigational therapy neflamapimod will be presented...

STOCKHOLM, Sweden, July 1, 2026 AlzeCure Pharma AB has announced a landmark global out-licensing and collaboration agreement with Danish...

SANTA ANA, Calif., July 2, 2026 NKGen Biotech announced that Chairman and Chief Executive Officer Paul Y. Song, M.D.,...

BRESSO, Milan, Italy, June 29, 2026 Zambon has announced that the Committee for Medicinal Products for Human Use (CHMP)...